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People living with HIV (PLHIV) are more likely than the general population to develop AIDS-defining malignancies (ADMs) and
several non-ADMs (NADMs). Information is lacking on survival outcomes and cause-specific mortality after cancer diagnosis
among PLHIV. We investigated causes of death within 5 years of cancer diagnosis in PLHIV enrolled in European and North
American HIV cohorts starting antiretroviral therapy (ART) 1996–2015, aged ≥16 years, and subsequently diagnosed with
cancer. Cancers were grouped: ADMs, viral NADMs and nonviral NADMs. We calculated cause-specific mortality rates (MR) after
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diagnosis of specific cancers and compared 5-year survival with the UK and France general populations. Among 83,856 PLHIV
there were 4,436 cancer diagnoses. Of 603 deaths after ADM diagnosis, 292 (48%) were due to an ADM. There were 467/847
(55%) and 74/189 (39%) deaths that were due to an NADM after nonviral and viral NADM diagnoses, respectively. MR were
higher for diagnoses between 1996 and 2005 versus 2006–2015: ADMs 102 (95% CI 92–113) per 1,000 years versus
88 (78–100), viral NADMs 134 (106–169) versus 111 (93–133) and nonviral NADMs 264 (232–300) versus 226 (206–248).
Estimated 5-year survival for PLHIV diagnosed with liver (29% [19–39%]), lung (18% [13–23%]) and cervical (75% [63–84%])
cancer was similar to general populations. Survival after Hodgkin’s lymphoma diagnosis was lower in PLHIV (75% [67–81%]).
Among ART-treated PLHIV diagnosed with cancer, MR and causes of death varied by cancer type, with mortality highest for
liver and lung cancers. Deaths within 5 years of NADM diagnoses were more likely to be from cancer than AIDS.
What’s new?
People with HIV live longer than they used to, thanks to advances in antiretroviral therapy. These improvements reduced the
incidence of AIDS-defining malignancies, such as Kaposi’s sarcoma, but the increased life expectancy has led to more
diagnoses of cancers not traditionally associated with HIV. Here, the authors studied cause-specific mortality among people
with HIV diagnosed with cancer. For those people, within 5 years after a cancer diagnosis, cause of death was more likely to be
cancer than AIDS. Survival rates after diagnosis varied by cancer type, but were similar to rates among the general population.
Background
People living with HIV (PLHIV) are more likely to develop
cancer than those not infected with HIV.1 This is the case not
only for AIDS-defining malignancies (ADMs), such as
Kaposi’s sarcoma and non-Hodgkin’s lymphoma2 but also for
some non-AIDS-defining malignancies (NADMs) such as anal
cancer.3,4 The introduction of effective combination antiretro-
viral therapy (ART) in 1996 led to a large decrease in inci-
dence of ADMs, because of control of HIV-replication and
improvement of immune status.5 With further improvements
in HIV care, particularly starting ART earlier in the course of
HIV disease, the incidence of ADMs has continued to
decline.6 Improvements treatment of HIV have resulted in
PLHIV living longer,7 increasing the risk of NADMs that are
associated with age in the general population.8
The incidence of ADMs and NADMs among PLHIV has
been well-studied2,9–11 but there is a lack of information on sur-
vival outcomes after specific cancer diagnoses. Few studies have
analysed 5-year survival after specific cancer diagnoses among
PLHIV12–20 and they were limited to prognosis after diagnosis
of ADMs,12,19 or included untreated PLHIV14,15 who have
worse prognosis than those on ART.5 Little information is
available on causes of death among PLHIV after diagnosis of
cancer. Patterns of survival after cancer diagnosis are affected
by several factors. Mortality rates vary considerably between
different types of cancer and stages of cancer.21 In the general
population, a death after a diagnosis of cancer may be more
likely due to that cancer than in PLHIV because of the compet-
ing risks of death due to AIDS and other HIV-related condi-
tions. There are also differences in the demographics of those
diagnosed with cancer in the general population compared to
PLHIV, which may explain differences in patterns of death.22,23
We studied cause-specific mortality after diagnosis of spe-
cific cancers to answer the question: what do PLHIV diagnose
with cancer die of? We also investigated changes over time in
5-year survival after cancer diagnosis in PLHIV and compared
this with survival in the general population of the United
Kingdom and France.
Materials and Methods
Participating cohorts
Data were combined from 10 HIV cohorts from Europe and
North America that participate in the Antiretroviral Therapy
Cohort Collaboration (ART-CC), which includes PLHIV aged
≥16 years who started ART after 1996.24 Ethics committees or
institutional review boards approved the cohorts, which used
standardised data collection methods, and followed-up
patients at least every 6 months. Included cohorts (listed in
the supplement) had information on diagnoses of both ADMs
(Kaposi’s sarcoma, cervical cancer and non-Hodgkin’s lym-
phoma) and NADMs (all other cancers) and had information
on cause of death available on ≥70% of deaths.
Data on cancer and mortality outcomes
Information on cancers was captured through medical records
at routine follow-up and hospitalisation diagnostic codes.
Cohorts validated cancer diagnoses, and provided dates of and
reasons for hospitalisations, which were considered due to
cancer if any of the reasons indicated cancer. Patients could
be diagnosed with multiple types of cancer on the date of a
hospitalisation. Available data on cancers was heterogeneous
between cohorts. Six of the 10 cohorts included used medical
records to gather information on cancer diagnoses, one cohort
had linkage to a cancer registry, one provided treatment for
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both HIV and cancer in the same centre, one had cancer diag-
noses reported to their database and verified by a clinician,
and one had heterogeneous methods of collection across their
sites (Supporting Information Table S1).
Cancer information in the form of ICD9 or ICD10 codes
was translated to defined subcategories for cancers within
HIV Cohorts Data Exchange Protocol (HICDEP) by AT, and
then verified by a clinician (MJG). We classified oral cavity
and pharynx squamous cell carcinoma (SCC), anal SCC, liver
hepatocellular carcinoma, vagina SCC, vulva SCC, penis SCC
and Hodgkin lymphoma as viral NADMs following Park
et al.25 (Supporting Information Table S2).
Information on mortality was gathered through linkage with
vital statistics agencies and hospitals or physician report, and
the active follow-up of participants. We used an adaptation of
the Coding of Death in HIV (CoDe) project protocol (www.
chip.dk/Tools-Standards/CoDe/About) to classify causes of
death, as described previously.26 Deaths due to opportunistic
infections secondary to complications of chemotherapy were
classified as caused by cancer rather than infection or AIDS.
Eligibility of patients and definition of follow-up time
Eligible patients had a baseline CD4 cell count measured
between 3 months before, and 2 weeks after, starting ART. Each
cohort specified a date after which cancer data were deemed to
be reliably collected: patients who initiated ART before then, or
had cancer diagnoses before then, were excluded. Similarly, each
cohort had a date before which cancer data were reliably col-
lected: cancer diagnoses after this date, or patients starting ART
following this, were excluded. Patients diagnosed with cancer
before starting ART were excluded. Patients were followed up
for a maximum of 5 years from the date of cancer diagnosis to
the earliest of death, loss to follow-up or cohort-specific database
administrative censoring. Patients with a gap of ≥1 year between
date last known to be alive and administrative censoring were
considered lost to follow-up (LTFU) and were censored
6 months after their last recorded measurement. If a patient had
multiple records of the same type of cancer, the second and sub-
sequent records were assumed to be multiple instances of treat-
ment or hospitalisations.
Statistical analysis
We compared characteristics at start of ART and at cancer
diagnosis of patients who were diagnosed with an ADM, viral
NADM and nonviral NADM. Because of the substantial
improvements in life expectancy of PLHIV since the introduc-
tion of ART, we stratified by period of cancer diagnosis
(1996–2005 and 2006–2015).7 Individuals with diagnoses of
multiple types of cancer could be in multiple groups. We tab-
ulated the frequency of specific cancers by period of diagnosis.
We investigated causes of death after diagnosis of ADMs,
viral NADMs, nonviral NADMs and after the most frequent
cancers with ≥30 diagnoses during each calendar period (cer-
vical cancer, head and neck cancers, Hodgkin’s Lymphoma,
liver cancer, Kaposi’s Sarcoma, lung cancer and
non-Hodgkin’s Lymphoma). Patients diagnosed with multiple
cancers or cancer groups were included in the analysis for
each cancer or cancer group, from the corresponding date of
diagnosis. However, if both cancers were the same type
(e.g. both NADMs), the patient was included only once in the
analysis for that group, from the date of diagnosis of the first
cancer. A patient could be included in an analysis for cancer
having been diagnosed with another type of cancer before or
during the follow-up period: a sensitivity analysis included
only patients diagnosed with one type of cancer. A sensitivity
analysis also investigated excluding patients aged above
70 years of age at the time of cancer diagnosis.
For each cancer group, we used Cox survival regression
models to estimate hazard ratios during the 5 years after can-
cer diagnosis, by period of cancer diagnosis (2006–2015 vs.
1996–2005) unadjusted and adjusted for CD4 count (0–99,
100–199, 200–349, 350–499, ≥500 cells/mm3), HIV-1 RNA
(0–499, 500–9,999, ≥10,000 copies/ml), and age (16–39,
40–49, 50–59, ≥60 years), all taken as the measurement closest
to and before the date of cancer diagnosis, combined
sex/transmission risk group, and stratified by cohort (ensuring
that all comparisons are among patients in the same cohort).
For each cancer group and specific cancer, we used Poisson
models to estimate mortality rates from all causes, AIDS,
ADMs, NADMs, other causes (not cancer), and unclassifiable/
unknown causes during the 5 years after cancer diagnosis,
separately for 1996–2005 and 2006–2015. Other causes of
death included all of the other coded deaths that were not due
to AIDS or cancers, for example, hepatitis, cardiovascular, sui-
cide, and so on. NADM deaths were not split as viral or non-
viral NADMs as often detailed enough coding information
was not available. We estimated both crude and standardised
mortality rates; standardised to the ART-CC population diag-
nosed with cancer, by age, sex and HIV transmission risk
group. In the analysis of liver cancer, we added viral hepatitis
as a specific cause of death because the CoDe system classifies
deaths from cancer associated with hepatitis under hepatitis
rather than NADM. Separately for each cancer group and by
calendar period of diagnosis, we used a competing risks
framework to generate 5-year cause-of-death-specific cumula-
tive incidence functions, which we plotted in a stacked graph.
We calculated 5-year survival after diagnosis of the seven
most frequently occurring cancers between 2006 and 2015,
and compared this to 5-year cancer survival in the general
population in the United Kingdom (2009–2013) (https://www.
cancerresearchuk.org/health-professional/cancer-statistics/survival)
and France (2005–2010),27,28 standardised to the age and sex
proportions of the ART-CC population diagnosed with the
cancer. Kaposi’s sarcoma and non-Hodgkin’s lymphoma were
excluded from this analysis as the burden among PLHIV
drives the general population burden. For head and neck can-
cers combined, detailed information on 5-year survival by age
group was not available for the United Kingdom.
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Data availability
The data that support the findings of the study are property
of the individual cohorts, which are listed on the ART-CC
website (http://www.bristol.ac.uk/art-cc/whoswho/). For data
availability, the individual cohorts should each be contacted
and data will be made available upon reasonable request,
where applicable.
Results
Records from 83,586 PLHIV providing 451,651 person-years
of follow-up were analysed. We included 4,436 records of
incident cancer for analysis, from 3,953 individual patients.
Median follow-up time was 3.3 years from first ADM diagno-
sis (interquartile range [IQR]: 0.7–5.0), while from first non-
viral NADM diagnosis it was 1.2 years (IQR: 0.3–3.6), and
from first viral NADM diagnosis 2.3 years (IQR: 0.6–5.0).
Table 1 shows the numbers of malignancies of different types
recorded in 1996–2005 and 2006–2015, as well as characteris-
tics of patients according to type of malignancy. Both median
age and median CD4 count at cancer diagnosis were lower for
individuals diagnosed with an ADM than with an NADM,
and for viral NADM compared to nonviral NADM. Both
median age and median CD4 count at cancer diagnosis
increased between 1996 and 2005 and 2006–2015, in each
cancer group. The viral load when starting ART was similar
across cancer groups and the two time periods, but the viral
load at diagnosis of cancer was higher for patients diagnosed
with ADMs than for those diagnosed with NADMs. Patients
diagnosed with ADMs were more likely to have AIDS when
starting ART than those diagnosed with NADMs. The most fre-
quently occurring cancers were the ADMs Kaposi’s sarcoma and
non-Hodgkin’s lymphoma, while lung cancer and Hodgkin’s
lymphoma were the commonest NADMs (Table 2). Supporting
Information Table S3 shows how characteristics, numbers of
cancers and deaths varies by cohort.
Prognosis after diagnoses of ADMs, viral NADMs and
nonviral NADMs
Among 2,162 PLHIV who were diagnosed with an ADM
292/603 (48%) deaths were due to an ADM. Among 2,047
diagnosed with an NADM 467/847 (55%) deaths were due to
an NADM. The proportions of deaths due to an NADM were
74/189 (39%) after a viral NADM diagnosis (n = 627) and
393/660 (60%) after a nonviral NADM diagnosis (n = 1,420).
Rates of mortality after ADM diagnosis were lower in the
later period: the unadjusted mortality rate ratio (MRR) for
2006–2015 versus 1996–2005 was 0.73 (95% CI 0.61, 0.86)
and the adjusted mortality rate ratio (aMRR) was 0.77 (0.65,
0.92). There was weaker evidence for such decrease for mor-
tality after viral NADM diagnoses: MRR 0.75 (0.55, 1.02) and
aMRR 0.76 (0.54, 1.07) and after nonviral NADM diagnoses:
MRR 0.80 (0.68, 0.94) and aMRR 0.84 (0.70, 1.00)—seen in
Table 3.
Table 3 shows crude and standardised rates of all-cause
and cause-specific mortality during the 5 years after cancer
diagnosis for the three cancer groups and by period of cancer
diagnosis, with Supporting Information Table S4 giving more
detailed information. Figure 1 shows patterns of 5-year cumu-
lative cause-specific mortality according to type of cancer and
calendar period. Among PLHIV diagnosed with an ADM,
standardised rates and 5-year cumulative incidence were
greater for mortality due to an ADM than for other causes of
death. AIDS was the second commonest cause of death in this
group for both periods. Similarly, mortality due to NADMs
was the leading cause of death among PLHIV diagnosed with
nonviral NADMs. The pattern of causes of death for PLHIV
diagnosed with viral NADMs was less clear: the standardised
rate of deaths coded as ‘other’ was nearly as great as the
standardised rate of deaths due to NADMs, particularly dur-
ing 2006–2015. Many of these deaths had a cause classified as
related to viral hepatitis. The proportion of PLHIV lost to fol-
low up in the 5-years after their cancer diagnosis was
16, 15 and 12% for those diagnosed with an ADM, viral
NADM and nonviral NADM, respectively. Supporting Infor-
mation Table S5 shows that there was little difference in mor-
tality rates when patients diagnosed with more than one type
of cancer were excluded from analyses, while Supporting
Information Table S6 shows that there was also little differ-
ence excluding those aged over 70 years at the time of cancer
diagnosis.
Prognosis after diagnosis of specific cancers
Table 4 shows mortality rates for the seven most commonly
diagnosed cancers: these were higher after diagnoses of
NADMs than ADMs and were very high for lung, liver, non-
Hodgkin’s lymphoma and head and neck cancers. For head
and neck and lung cancer, the very high rates of NADM mor-
tality suggest that cause of death was predominantly due to
the diagnosed cancer. This was also the case for non-
Hodgkin’s lymphoma, for which standardised rates of ADM
mortality were high. A substantial proportion of deaths from
liver cancer had been classified as due to viral hepatitis by our
process for assigning CoDe cause of death classifications: these
are shown as liver-related in Table 4. Table 4 also contains
unadjusted and adjusted MRRs for cancers diagnosed between
2006 and 2015 compared to 1996–2005. Evidence of reduc-
tions in MRRs between the two-calendar year periods was
seen for liver cancer: MRR 0.61 (95% CI 0.38, 1.00) and
aMRR 0.41 (95% CI 0.22, 0.76), and non-Hodgkin’s lym-
phoma: MRR 0.62 (95% CI 0.51, 0.77) and aMRR 0.65 (95%
CI 0.52, 0.81).
Estimated 5-year survival after diagnosis of cervical, head
and neck, liver and lung cancer during 2006–2015 was similar
in PLHIV to survival in people in the general population diag-
nosed with these cancers in the United Kingdom and France
(Fig. 2). Five-year survival for PLHIV diagnosed with
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Hodgkin’s lymphoma was lower than in the general popula-
tion diagnosed with that cancer.
Discussion
Among PLHIV diagnosed with cancer, deaths due to an ADM
were the leading cause of death after an ADM diagnosis while
deaths due to an NADM were the leading cause of death after
diagnosis of nonviral NADMs. Deaths after diagnosis with
viral NADMs were most likely to be due to a NADM or due
to other causes, many of which were classified as due to viral
hepatitis. PLHIV diagnosed with nonviral NADMs had much
higher mortality rates than those diagnosed with ADMs, or
viral NADMs. Mortality rates after diagnosis of cancer were
lower during 2006–2015 than 1996–2005: these declines were
not explained by changes in CD4 count and viral load at can-
cer diagnosis. Possible explanations are earlier cancer stage at
diagnosis due to improvements in screening,29 improvements
in care among PLHIV,7,30 greater awareness of drug–drug
interactions,31 availability of more effective treatment for
cancer32 or patients with higher CD4 counts being able to
withstand more doses of chemotherapy.33
The most common cancers reported were the ADMs
Kaposi’s sarcoma, non-Hodgkin’s lymphoma, and cervical can-
cer and the NADMs lung cancer, Hodgkin’s lymphoma, anal
cancer, head and neck cancers and liver cancer. For lung cancer,
head and neck cancer and non-Hodgkin’s lymphoma most
deaths were likely to have been caused by the diagnosed cancer.
Five-year survival was low after diagnosis of liver cancer (as in
the general population), but the underlying cause of death
was often classified as viral hepatitis. Five-year survival
among PLHIV diagnosed with liver, lung and cervical can-
cers was similar to survival reported from general population
cancer registries, but it was lower for PLHIV diagnosed with
Hodgkin’s lymphoma.
Table 1. Numbers and characteristics of patients diagnosed with an AIDS-defining malignancy (ADM), viral non-AIDS defining malignancy
(NADM) or a nonviral NADM, by calendar period of diagnosis
Characteristics at start of
ART and at diagnosis of cancer
Cancer diagnosis 1996–2005 Cancer diagnosis 2006–2015
ADM
(n = 1,091)
NADM viral
(n = 186)
NADM nonviral
(n = 424)
ADM
(n = 1,071)
NADM viral
(n = 441)
NADM nonviral
(n = 996)
Age, years: median (IQR)
ART start 38 (32, 47) 39 (34, 47) 43 (36, 53) 39 (32, 47) 41 (34, 48) 46 (38, 54)
Diagnosis of cancer 40 (34, 48) 43 (36, 50) 45 (39, 56) 42 (36, 50) 46 (40, 53) 51 (44, 60)
CD4 cells/mm3, median (IQR)
ART start 125 (41, 264) 183 (68, 320) 160 (67, 301) 170 (60, 300) 201 (98, 322) 211 (82, 330)
Diagnosis of cancer 170 (64, 320) 239 (103, 408) 263 (119, 435) 238 (96, 416) 350 (185, 550) 414 (240, 631)
RNA copies/ml log median (IQR)
ART start 5.1 (4.6, 5.6) 4.9 (4.2, 5.3) 5.0 (3.3, 5.5) 5.1 (4.6, 5.5) 4.9 (4.2, 5.4) 5.0 (4.4, 5.4)
Diagnosis of cancer 3.2 (2.3, 5.0) 2.5 (1.7, 4.1) 2.3 (1.7, 3.5) 2.4 (1.7, 4.7) 1.7 (1.6, 1.8) 1.7 (1.5, 1.7)
Sex and transmission risk group, n (%)
MSM 549 (50%) 78 (42%) 140 (33%) 554 (52%) 225 (51%) 369 (37%)
Male PWID 68 (6%) 36 (19%) 60 (14%) 51 (5%) 54 (12%) 107 (11%)
Female PWID 34 (3%) 4 (2%) 17 (4%) 28 (3%) 9 (2%) 38 (3%)
Male heterosexual 184 (17%) 46 (25%) 95 (22%) 186 (17%) 82 (19%) 257 (26%)
Female heterosexual 144 (13%) 13 (7%) 67 (16%) 173 (16%) 40 (9%) 159 (16%)
Male other/unknown 88 (8%) 9 (5%) 41 (10%) 60 (6%) 24 (5%) 48 (5%)
Female other/unknown 24 (2%) 0 (0%) 4 (1%) 19 (2%) 7 (2%) 18 (2%)
AIDS at ART start
No 526 (48%) 140 (75%) 281 (66%) 644 (60%) 329 (75%) 715 (72%)
Yes 565 (52%) 46 (25%) 143 (34%) 427 (40%) 112 (25%) 281 (28%)
Hepatitis C virus at ART start
Negative 866 (79%) 126 (68%) 290 (68%) 859 (80%) 318 (72%) 739 (74%)
Positive 93 (9%) 41 (22%) 74 (17%) 91 (9%) 87 (20%) 141 (14%)
Missing/unknown 132 (12%) 19 (10%) 60 (14%) 121 (11%) 36 (8%) 116 (12%)
Ever smoked
No 215 (20%) 28 (15%) 36 (8%) 340 (32%) 105 (24%) 218 (22%)
Yes 209 (19%) 58 (31%) 120 (28%) 335 (31%) 193 (44%) 469 (47%)
Missing/unknown 667 (61%) 100 (54%) 268 (63%) 396 (37%) 143 (32%) 309 (31%)
Abbreviations: ART, antiretroviral therapy; MSM, men who have sex with men; PWID, people who inject drugs.
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Comparisons with other literature
To the best of our knowledge, our study is the first to analyse
cause-specific mortality among PLHIV diagnosed with a range
of specific cancers, spanning multiple countries. A large
registry-linkage study in the USA found much higher mortal-
ity rates after diagnosis for comparable cancers and also found
that a higher percentage of the mortality of PLHIV diagnosed
with NADMs was due to AIDS.34 This difference could be
due to earlier diagnosis of cancer in our cohorts compared to
their registry-linkage study, or because all of the patients in
our analysis were on ART at the time of the cancer diagnosis,
which was not necessarily the case in the USA study.34 A US
study among elderly adults found higher cancer-specific mor-
tality for prostate and breast cancer for PLHIV compared to
HIV-negative people, however, we did not look at these indi-
vidual cancers in our study.35 A small German study found
that after just over a year, 87% of the deaths that occurred
after diagnosis of lung cancer were due to lung cancer.13 This
observation is concordant with our findings, although we had
to infer that death due to NADM was due specifically to lung
cancer. A general population study in the USA on diffuse
large B-cell lymphoma patients found that 24% of deaths were
attributed to noncancer causes,36 a lower figure than in our
study. However, mortality rates depend on the stage of cancer
at diagnosis, age and demographics of the patients, which can
vary between health systems, making comparisons difficult.
Several HIV cohort studies have estimated 5-year survival
after cancer diagnoses. Five-year survival after diagnosis of
non-Hodgkin’s lymphoma was lower in the Collaboration of
Observational HIV Epidemiology Research in Europe
(COHERE), a European study, than in ART-CC (55% vs.
71%), but our study included more recent data.16 The Italian
Cancer and AIDS registries linkage study found much lower
5-year survival probabilities than ART-CC after several spe-
cific cancers, for example, liver cancer 8% vs. 26%, but our
study was during the early ART period and included PLHIV
not on ART who had an AIDS diagnosis.12 Another Italian
study which included PLHIV not on ART found similar
5-year survival to ART-CC after a diagnosis of Hodgkin’s
lymphoma.14 A separate Italian cohort study, which also
included PLHIV not on ART estimated 4-year survival con-
cordant with our 5-year survival for liver cancer, but much
lower survival for Hodgkin’s lymphoma (30% vs. 71%),
lung cancer (6% vs. 16%), and cervical cancer (53% vs.
86%).15 A large French study which found improved sur-
vival between 2005 and 2009 compared to 1997–2000 for
some haematological cancers and for ADMs, but not for
solid cancers, reported higher 5-year survival for Hodgkin’s
lymphoma than in ART-CC (87% vs. 71%), and similar
survival for lung and liver cancers.17 Compared to ART-
CC, a study in the USA found survival was lower for lung
cancer (10% vs. 16%), and higher for Hodgkin’s lymphoma
(83% vs. 71%), possibly due to differences in the demo-
graphics between the two populations or the inclusion of
PLHIV not on ART in the study from the USA.18
Strengths and limitations
We analysed a large dataset of PLHIV receiving care in
clinical cohorts in Western Europe and North America: our
findings should be generalisable to PLHIV on ART in high-
income regions with recent cancer diagnoses. The size of our
dataset enabled analyses of a wider range of specific cancers
than previous studies. Most cohorts linked to death registries,
but some PLHIV diagnosed with cancers with poor survival
may have died after being lost to follow-up, so we may have
underestimated mortality rates.37 Information on cancer stage
at diagnosis was not available: this may have resulted in some
misclassification of precancerous lesions as cancer which
could have biased survival estimates upwards. However, we
focused our analyses on cancers that are more robustly vali-
dated and performed checks to remove precancers from the
analysis.
Table 2. Cancers reported in the ART-CC, diagnosed 1996–2005 and
2006–2015
Cancer type n: 1996–2005 n: 2006–2015 n: Total
Kaposi’s sarcoma 616 547 1,163
Non-Hodgkin’s lymphoma 449 464 913
Lung cancer 116 255 371
Hodgkin’s lymphoma 109 196 305
Anal cancer 22 124 146
Cervical cancer 51 91 142
Head and neck cancers 42 96 138
Liver cancer 42 95 137
Leukaemia (all types) 28 61 89
Prostate cancer 16 62 78
Breast cancer 16 46 62
Bladder cancer 14 43 57
Connective tissue cancers 22 29 51
Malignant melanoma 10 40 50
Colon cancer 7 39 46
Brain cancer 17 19 36
Pancreatic cancer 5 25 30
Kidney/renal cancer 6 23 29
Stomach cancer 9 20 29
Rectal cancer 7 19 26
Uterus cancer 7 17 24
Testicular cancer 5 13 18
Penis cancer 4 12 16
Gynaecologic cancer 5 10 15
Bone cancer 6 7 13
Oesophageal cancer 2 10 12
Gall bladder cancer 2 4 6
Lip cancer 1 3 4
Not including metastasis, multiple myelomas, those of unspecified site,
or unknown cancers.
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Figure 1. Cumulative cause-specific mortality of patients from first diagnosis of ADM (upper), viral NADM (middle) and nonviral NADM (lower),
stratified by period of cancer diagnosis (1996–2005 and 2006–2015). Abbreviations: ADM, AIDS-defining malignancy; NADM, Non-AIDS defining
malignancy. Cumulative incidence functions were generating using a competing risks framework. [Color figure can be viewed at wileyonlinelibrary.com]
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We did not have conclusive data on cancer treatment such
as chemotherapy and radiotherapy, which is a major prognostic
factor.32 We also do not know if all people received the same
standard of treatment across the different countries and
regions.21 Survival comparisons with the general population
may have been impacted by higher rates of smoking in PLHIV,
but we were unable to adjust for this and other lifestyle factors.
Due to the lack of universal linkage to cancer registries, we
could not examine cancer incidence as some diagnoses might
not have been recorded by the cohorts. Cause-specific mortality
for PLHIV with recorded diagnosis of cancer should not be
affected by this issue. We excluded those diagnosed with cancer
who subsequently started ART due to uncertainty in timing of
HIV infection and diagnosis. The cause of death information in
ART-CC was not specific enough to determine causes of death
due to specific cancers, for example, some causes of death were
only able to be coded as an NADM, rather than, for example,
lung cancer. Therefore, our analyses are assuming that if, using
the same example, a death was due to an NADM cancer after a
diagnosis of lung cancer, then that death was most likely due to
lung cancer. Additionally, for this analysis, we were unable to
separate out deaths due to opportunistic infections caused by
complications of chemotherapy as it was not available in
HICDEP as a category of deaths. Classification of some deaths
as AIDS-related will have been based on a previous AIDS diag-
nosis, so some deaths may have been misclassified as due to
infection rather than cancer, when the immediate cause was a
complication of chemotherapy and the underlying cause, can-
cer, was not recorded. However, most cohorts recorded the
underlying cause of death, or multiple causes of death, as well
as the immediate cause.
Implications
The improvement in survival of PLHIV diagnosed with cancer
in 2006–2015 compared to 1996–2005 may reflect improvements
in care among PLHIV, such as increased cancer screening
resulting in earlier detection of cancers, which are easier to treat,
or more effective cancer treatment.32 Another explanation could
be improvements in ART resulting in better immunological sta-
tus at cancer diagnosis, leading to more patients being able to
tolerate chemotherapy.33
We reported estimates of 5-year survival for several types
of cancer. This information is important for clinicians and is
easy to communicate to patients. The comparison with 5-year
survival in the general population quantifies the disparity that
exists in some cancers and is a benchmark for future progress
towards equalising survival rates. Although mortality rates
decreased between 1996–2005 and 2006–2015, survival was
worse for PLHIV diagnosed with Hodgkin’s lymphoma than
in the general population, possibly due to more aggressive
forms of the cancer among PLHIV, interactions between ART
and chemotherapy, or delayed use of new therapeutic options
compared to the general population. More positively, for cer-
vical, head and neck, liver and lung cancers there was no evi-
dence of disparity in survival after cancer diagnosis between
PLHIV and the general population. The publication and dis-
semination of such information may encourage PLHIV to be
more proactive in being screened for cancer.
The population of PLHIV is ageing due to increased life
expectancy attributable to more effective ART.16 As the cohort of
PLHIV ages, they will be at increased risk of cancers not consid-
ered related to HIV that were previously rarely seen.8 As with the
general population,38 many of these cancers are linked to lifestyle
factors and comorbidities such as smoking and hepatitis C virus,
both major sources of mortality among PLHIV.39–41 Emphasis
should be placed on targeting such behaviours and treating co-
morbidities such as chronic viral hepatitis in order to prevent
cancer.
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